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Human noroviruses are a major cause of epidemic and sporadic gastroenteritis worldwide and can chroni-
cally infect immunocompromised patients. Efforts to develop effective vaccines and antivirals have been hin-
dered by the uncultivable nature and extreme genetic diversity of human noroviruses. Although they remain a
particularly challenging pathogen to study, recent advances in norovirus animal models and in vitro cultiva-
tion systems have led to an increased understanding of norovirus molecular biology and replication, patho-
genesis, cell tropism, and innate and adaptive immunity. Furthermore, clinical trials of vaccines consisting of
nonreplicating virus-like particles have shown promise. In this review, we summarize these recent advances
and discuss controversies in the field, which is rapidly progressing toward generation of antiviral agents and
increasingly effective vaccines.Introduction
Human noroviruses (HuNoVs) are a leading cause of gastroen-
teritis outbreaks across the globe and severe childhood diarrhea
across the globe (Koo et al., 2013; Payne et al., 2013). HuNoV
gastroenteritis is characteristically an acute illness. However,
chronic HuNoV infection of immunocompromised persons pre-
sents a debilitating and often intractable problem (Bok and
Green, 2012). Further, prolonged asymptomatic HuNoV infection
and shedding may contribute to spread of the virus. Importantly,
in animal models NoV infection can interact with allelic host
genome variations to induce inflammatory bowel disease-like
phenotypes (Basic et al., 2014; Cadwell et al., 2010), raising
the possibility that NoV infection may trigger lasting effects in
the gut long after the resolution of an acute illness.
Despite recent progress in HuNoV vaccine development,
several key challenges remain in assessing the efficacy of vac-
cines and antiviral drugs. First, the lack of a robust HuNoV cell
culture system limits direct study of these viruses (Duizer et al.,
2004; Herbst-Kralovetz et al., 2013; Lay et al., 2010; Papafrag-
kou et al., 2013; Straub et al., 2007). Second is the extreme
genetic heterogeneity among strains (Green, 2013; Kroneman
et al., 2013) and the emergence of new variants every 2–3 years,
as represented by the recent pandemic GII.4 Sydney HuNoV
(Barclay et al., 2013). Third, protective immunity to natural
HuNoV infections is complicated by an apparent lack of hetero-
typic protection among strains (Bok et al., 2011; Wyatt et al.,
1974). Moreover, there is evidence that homotypic responses
are ineffective or short-lived at best (Johnson et al., 1990; Parrino
et al., 1977), although circulating strains may elicit short-term
herd immunity (Lindesmith et al., 2012).
Here, we summarize recent advances in the NoV field and
discuss their potential in helping achieve successful prevention
and control. We also point out controversies in the field regarding
the relevance of NoV studies in animal models to human disease.668 Cell Host & Microbe 15, June 11, 2014 ª2014 Elsevier Inc.As with any human infectious diseases, caveats and limitations
are inherent to studying NoV in animal models, and any conclu-
sions drawn from animal studies will need to be validated in the
natural host. Regardless of the ultimate answer as to how closely
animal NoV infection mimics HuNoV infection, the murine noro-
virus (MuNoV) system provides a unique opportunity to answer
fundamental questions about viral immunity, especially in the in-
testine using a bona fide mouse virus and a genetically tractable
experimental host. Here we emphasize recent findings with
the greatest potential to advance vaccine and antiviral drug
development as well as key remaining questions in NoV biology
research.
Molecular Virology of Noroviruses
NoVs are small, positive sense, nonenveloped RNA viruses
comprising one genus of the family Caliciviridae. The genus is
segregated into at least five and possibly six genogroups (gen-
ogroups I–VI), of which genogroups I, II, and IV contain primarily
human viruses associated with gastroenteritis (Green, 2013;
Kroneman et al., 2013). Genogroups III, V, and VI are comprised
of bovine NoVs, MuNoVs, and canine NoVs, respectively. NoV
genogroups are further subdivided into genotypes, or clusters,
based on genetic similarity. Specific strains are referred to by
their genogroup and genotype (e.g., a GII.4 virus segregates in
genogroup II and genotype 4). The viral genome is 7.4–7.7 kb
in length and is organized into three or four open reading frames
(ORFs) (Figure 1). The 50 proximal ORF1 encodes a large poly-
protein that is cleaved by a virus-encoded protease (Pro; NS6)
into at least six mature nonstructural proteins including the viral
RNA-dependent RNA polymerase (NS7; RdRp). NoVs have only
a single major structural protein, which is encoded by ORF2.
This capsid protein, referred to as VP1, is organized into a
well-conserved internal shell (S) domain and a protruding (P)
domain forming dimeric VP1 arches; the P domain can be further
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Figure 1. Norovirus Virulence Determinants
The NoV genome is depicted. The 50 proximal ORF1 (shown in orange) encodes a nonstructural polyprotein, which is cleaved into six mature products by the
virally encoded protease (NS6 or Pro). Other nonstructural proteins include NS1/2 (also referred to as p48), NS3 (NTPase), NS4 (p22), NS5 (VPg), and NS7 (the
RNA-dependent RNA polymerase; RdRp). ORF2 encodes the capsid protein referred to as VP1; this protein can be divided into shell (S; shown in yellow) and
protruding (P) domains, and the P domain further subdivided into the P1 stalk domain (shown in blue) and the hypervariable P2 domain comprising the tips of the
arches (shown in red). ORF3 encodes the minor structural protein VP2, and ORF4 of MuNoV genomes encodes a newly defined protein called virulence factor 1,
or VF1. NoV genomes are covalently linked to VPg at their 50 ends and polyadenylated at their 30 ends. Studies in the MuNoV model system have identified a
number of NoV virulence determinants, which are indicated along the viral genome.
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face-exposed P2 subdomain that localizes to the tips of the
arches (Prasad et al., 1994). ORF3 encodes a minor structural
protein called VP2. The two structural proteins VP1 and VP2
are translated from a subgenomic RNA. For MuNoVs, a fourth
ORF overlaps ORF2; translation from this alternative ORF4
produces a recently identified protein virulence factor 1 (VF1)
(McFadden et al., 2011; Thackray et al., 2007). The 50 ends of
NoV genomic and subgenomic RNAs are covalently linked to
a small virus-encoded protein known as VPg, and the 30 ends
are polyadenlyated.
Understanding the mechanisms of HuNoV genome translation
and replication has been hampered by the lack of a cell culture
system. Advances in the area, namely the development of a
HuNoV replicon (Chang et al., 2006), the discovery of cultivable
MuNoVs (Karst et al., 2003; Wobus et al., 2004), and transient
in vitro expression assays using transfected viral genomes
(Guix et al., 2007), have enabled significant progress. The
MuNoV system has become the model of choice for the majority
of molecular studies due to the availability of cell culture and
reverse genetics systems (Chaudhry et al., 2007; Ward et al.,
2007; Wobus et al., 2004). Thorne and Goodfellow (2014)
recently reviewed NoV gene expression and replication, so
here we briefly highlight work that could lead to new approaches
in drug discovery and design.
The first step in intracellular NoV replication is translation of the
nonstructural proteins from genomic RNA molecules. Several
lines of evidence highlight a role for VPg in viral genome transla-
tion initiation: first, removal of VPg from the 50 end of NoV
genomes dramatically diminishes their infectivity (Chaudhry
et al., 2006; Guix et al., 2007). Second, the NoV VPg interacts
with cellular translation initiation factors (Chaudhry et al., 2006;
Daughenbaugh et al., 2006, 2003; Goodfellow et al., 2005).
Because VPg-mediated translation initiation is a process unique
to the virus, it represents a strong candidate for antiviral drug
design. After nonstructural protein synthesis, genome replication
occurs via the viral RdRp in replication complexes. Characteriza-
tion of the NoV RdRp has demonstrated both primer-dependent
and de novo mechanisms of RNA synthesis (Belliot et al., 2005;
Fukushi et al., 2004; Rohayem et al., 2006), the former utilizing
the VPg protein as a peptide primer facilitating the covalent link-age of VPg to the 50 end of the viral genome. The NoV RdRp
is also a logical target for drug development based on its com-
monalities to other more widely studied viral RdRp enzymes
for which many antiviral drugs have been developed. Indeed,
one such drug, 20-C-methylcytidine, has shown promise in treat-
ing MuNoV infections in the mouse model (Rocha-Pereira et al.,
2013). The NoV replication complex is associated with virus-
induced intracellular membranous vesicles (Hyde et al., 2009).
The localization of MuNoV-1 nonstructural proteins to mem-
branes of the early and late secretory pathway has suggested
a role for these pathways in replication complex formation
(Hyde and Mackenzie, 2010). Replication complex formation
also involves the cytoskeletal network, allowing the establish-
ment of the replication complex in close proximity to the micro-
tubule organizing network (Hyde et al., 2012).
The HuNoV replicon system, developed by substituting the
ORF2 gene of the GI.1 Norwalk virus with a neomycin resistance
gene (Chang et al., 2006), has proven invaluable in the identifica-
tion of small molecule inhibitors of viral replication (e.g., ribavirin,
cyclic sulfamides, deubiquitinases) (Arias et al., 2013). Further-
more, analysis using this approach has increased understanding
of the effect of NoV replication on host cell processes, high-
lighting the significant role of cholesterol levels on HuNoV repli-
cation (Chang, 2009). The observation that low cholesterol
stimulates replication has since been corroborated using a pig
model of HuNoV infection (Bui et al., 2013; Jung et al., 2012).
However, a number of important unanswered questions
regarding NoV replication remain. These include the relevance
of findings in animal viruses to replication of HuNoVs, questions
that await the development of a robust HuNoV replication sys-
tem. For all NoVs, key questions include the need for a detailed
understanding of the function of cellular proteins required for
NoV genome translation and replication, the processes by which
NoV subgenomic RNA is synthesized, and the mechanisms for
formation and function of themembrane-bound replication com-
plex. Moreover, the contribution and the impact of virus infection
on cellular processes such as ubiquitination, nuclear-cyto-
plasmic export, cell death, and protein trafficking have yet to
be fully explored. Gaining a better understanding of the cellular
processes involved in, and required for, NoV replication may
lead to therapeutic approaches that circumvent the problemsCell Host & Microbe 15, June 11, 2014 ª2014 Elsevier Inc. 669
Figure 2. Human Norovirus Mouse Model
The schematic overview summarizes the findings
of Taube et al. (2013). (Top) Balb/cmice deficient in
the recombination activating gene (RAG) and
common gamma chain (gc) were ‘‘humanized’’
with human CD34+ positive stem cells following
irradiation. Mice were infected with filtered
HuNoV-containing stool by combined peroral
(p.o.) and intraperitoneal (i.p.) routes. Infection was
detected by measuring increased genome titers
over input by qRT-PCR and viral protein expres-
sion by immunohistochemistry (IHC). The image
shows two VP1-positive Kupffer cells. (Middle)
Balb/c RAG/gc-deficient mice were infected with
HuNoV-containing stool filtrate by the oral and/or
intraperitoneal routes, and infectionwasmeasured
as above. The image shows twoNS6-positive cells
in the spleen. No infection was seen following oral
infection. (Bottom) B6/B10 RAG/gc-deficient mice
or wild-type (WT) Balb/c were infected by the p.o.
or i.p. routes, but no increases in viral genome
titers over input were detected, demonstrating that
both the immune status and the genetic back-
ground are important susceptibility factors in this
model.
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geting viral proteins directly.
Cell Tropism of Noroviruses
While most enteric pathogens infect intestinal epithelial cells
(IECs), and NoV virions can be transcytosed through IECs,
extensive attempts to cultivate HuNoVs andMuNoVs in epithelial
cells have been unsuccessful (Duizer et al., 2004; Gonzalez-Her-
nandez et al., 2013; Marionneau et al., 2002; Wobus et al., 2004).
Although one group has reported productive HuNoV infection
using 3D organoid models of intestinal epithelium (Straub
et al., 2007, 2011, 2013), multiple independent attempts to repli-
cate these cell culture systems have failed (Herbst-Kralovetz
et al., 2013; Papafragkou et al., 2013; Takanashi et al., 2014).
Collectively, these data argue that ex vivo cultured IECs are likely
not productively infected by NoVs. However, it is important
to note that viral antigen can be detected in IECs of gnotobiotic
piglets and calves infected perorally (p.o.) with a GII.4 HuNoV
(Cheetham et al., 2006; Jung et al., 2012; Souza et al., 2008)
and in STAT1/ mice infected with a MuNoV (Mumphrey
et al., 2007), suggesting that cellular tropism may be influenced
by the immune status of the host and leaving open the possibility
that IECs are targeted by NoVs in vivo.
Compelling evidence has accumulated in recent years,
demonstrating that a major target of NoVs is professional anti-
gen-presenting cells (APCs). MuNoVs efficiently replicate in pri-
mary dendritic cells and macrophages, as well as a number of
macrophage-like cell lines, in vitro (Wobus et al., 2004). Further-
more, viral antigen has been detected in cells costained with a
macrophage marker and cells morphologically resembling den-
dritic cells and macrophages in tissue sections from animals in-
fectedwith aMuNoV (Mumphrey et al., 2007; Perdue et al., 2007;
Ward et al., 2006; Wobus et al., 2004). With regard to HuNoVs,
viral antigen was detected in lamina propria cells of an intestinal
biopsy sample from a GI.1 HuNoV-infected person (Lay et al.,
2010). Similarly, an inactivated GII.4 HuNoV was found to bind670 Cell Host & Microbe 15, June 11, 2014 ª2014 Elsevier Inc.to lamina propria cells and submucosal Brunner’s glands, but
not IECs, when incubated with human duodenum tissue sections
(Chan et al., 2011). Chimpanzees infected intravenously (i.v.) with
a GI.1 HuNoV contain virus capsid antigen-positive intestinal
dendritic cells, but not macrophages or epithelial cells (Bok
et al., 2011). Finally, immunodeficient mice infected intraperito-
neally (i.p.) with a pool of genogroup II HuNoVs display structural
and nonstructural antigen-positive macrophage-like cells in their
spleens and livers (Taube et al., 2013) (Figure 2). While dendritic
cells and macrophages are well-accepted targets of MuNoV
infection, more recent data reveal that B cells are also permissive
to NoVs. The B cell zones of Peyer’s patches from MuNoV-1-
infected STAT1/ and IL-10/ mice contain detectable viral
nonstructural protein and viral genome, respectively (Basic
et al., 2014; Mumphrey et al., 2007), and capsid-positive
duodenal B cells are detectable in chimpanzees infected with a
GI.1 HuNoV (Bok et al., 2011). Thus, all types of professional
APCs and some lymphocytes appear to be permissive for
NoVs. The ability of NoVs to infect intestinal immune cells un-
doubtedly has a significant impact on NoV pathogenesis and
the host immune response to NoV infection. Unfortunately, ef-
forts to propagate HuNoVs in APCs have been unsuccessful
so far (Lay et al., 2010). It is important to note, however, that
these data do not preclude a possible role for other cell types
in NoV pathogenesis or immunity. Studies assessing the role
for additional cell types are therefore an important priority.
Based on the developing model that NoVs productively infect
intestinal immune cells, but not (to date) IECs, NoVs may well
employ strategies to overcome the intestinal epithelial barrier
to access underlying target cells. Consistent with this, HuNoVs
can be internalized by IECs in culture in the absence of produc-
tive infection (e.g., Marionneau et al., 2002). Moreover, MuNoVs
can be transcytosed across a monolayer of polarized confluent
IECs in culture via M-like cells without productive infection or
disruption of tight junctions (Gonzalez-Hernandez et al., 2013).
M cells are specialized intestinal epithelial cells in the
Cell Host & Microbe
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gens, including pathogens, in the lumen of the host to deliver
them to underlying immune cells. Depletion of M cells from
mice reduced MuNoV titers (Gonzalez-Hernandez et al., 2014),
suggesting that MuNoVs exploit the special function of M cells
to initiate infection of the host.
A major unresolved question in the area of NoV cell tropism is
the mechanism of resistance to HuNoV replication in cultured
cells. Based on the observation that a HuNoV virus-like particle
(VLP) can bind to and be internalized by IECs but cannot repli-
cate in these cells, it was initially speculated that the block oc-
curs after viral entry (Marionneau et al., 2002). However, it has
been demonstrated more recently that a HuNoV can overcome
the restriction to in vitro growth if entry and genome uncoating
are bypassed via genome transfection into nonsusceptible cells,
although this is inefficient (Guix et al., 2007). MuNoVs replicate
efficiently in otherwise nonsusceptible cells, including in human
cells, upon viral genome transfection (Chaudhry et al., 2007),
clearly demonstrating that early steps such as receptor binding,
entry, and/or genome uncoating likely regulate susceptibility to
NoV infection. The entry receptors used by NoVs have yet to
be identified, although there is extensive evidence that they
use carbohydrates as attachment receptors. We will not discuss
carbohydrate usage in this review since it has been the subject of
numerous recent reviews (e.g., Tan and Jiang, 2014). Many
groups are aggressively testing other types and sources of
human IECs and APCs, HuNoV strains, and innovative culture
conditions to overcome this frustrating hurdle to NoV research.
Elucidating Norovirus Pathogenesis in Animal Models
The pathogenic mechanisms of HuNoV infection are not fully
elucidated, but advances in animal models are facilitating prog-
ress in this area (Table 1). HuNoVs can experimentally infect
several animal species with variable clinical outcome. Gnotobi-
otic pigs and calves inoculated p.o. with a GII.4 or a GII.g/
GII.12 HuNoV develop mild diarrhea (Cheetham et al., 2006;
Souza et al., 2008; Takanashi et al., 2011) and thus can be
used to study pathogenic mechanisms of NoV-induced disease.
Animal models that support asymptomatic HuNoV infection are
chimpanzees infected p.o. or i.v. with a GI.1 HuNoV (Bok et al.,
2011; Wyatt et al., 1978) and immunocompromised RAG/
gamma chain-deficient (RAG/gc/) mice on a Balb/c back-
ground infected i.p. with a pool of genogroup II viruses (Taube
et al., 2013). In this mouse model of HuNoV infection, although
mice do not develop disease, they display increased viral
genome levels in the intestinal tract and systemic sites over input
titers 1–2 days postinfection, and viral nonstructural protein can
be detected in the liver and spleen (Figure 2), supporting in vivo
viral propagation (Taube et al., 2013). However, it should be
noted that further validation of this model is required before
it can be applied for preclinical testing of therapeutics and
vaccines.
In addition to animal models of HuNoV infection, the study of
MuNoVs has provided substantial insights into NoV pathogen-
esis and immunity (Karst, 2010a; Karst et al., 2003; Wobus
et al., 2006). MuNoVs are transmitted fecal-orally, replicate in
the intestine, and cause quantifiable intestinal pathology, but
not overt diarrhea in wild-type murine hosts (Hickman et al.,
2014; Hsu et al., 2005; Karst et al., 2003; Mumphrey et al.,2007). Malnourished mice are susceptible to more severe
MuNoV infections as defined by modest weight loss, are
impaired in controlling infection in certain tissues, and display
delayed viral clearance compared to their healthy counterparts
(Hickman et al., 2014). This model should be useful for defining
the nature of NoV infections in the context of malnutrition.
Although HuNoVs can cause debilitating gastroenteritis, avail-
able evidence indicates that this disease is associated with only
modest intestinal pathology (Blacklow et al., 1972; Dolin et al.,
1975; Schreiber et al., 1973, 1974). No gross histological
changes have been observed in the intestines of HuNoV-in-
fected gnotobiotic pigs (Bui et al., 2013; Cheetham et al.,
2006), chimpanzees (Bok et al., 2011), or immunocompromised
mice (Taube et al., 2013); likewise, MuNoV-infected mice show
no gross histological abnormalities (Mumphrey et al., 2007).
Similarly, HuNoV and MuNoV infections induce only modest
inflammation of the intestinal lamina propria (Blacklow et al.,
1972; Dolin et al., 1975; Mumphrey et al., 2007; Schreiber
et al., 1973, 1974; Souza et al., 2008; Troeger et al., 2009) and
apoptosis of IECs (Cheetham et al., 2006; Mumphrey et al.,
2007; Troeger et al., 2009). Thus, one remaining question in
NoV pathogenesis is how the virus causes severe gastroenteritis
while inducing only modest intestinal pathology, inflammation,
and apoptosis. Extrapolating to other types of infections,
possible mechanisms include induction of pathogenic cytokines
or expression of an enterotoxin.
Another question actively being investigated using animal
models is the main site(s) of NoV replication. From these studies,
it may be possible that general features of NoV infection can be
extrapolated, although not all features are conserved across all
model systems (Table 1). NoVs are detected at very low levels
in the stomachs of infected hosts, but there is no evidence that
the virus replicates in this fastidious environment. Further,
NoVs can be detected along the length of the small and large in-
testine, although virus strain-specific preferences for specific in-
testinal segments exist. It should be noted that colonic infection
by HuNoVs has not been analyzed, so it remains unclear whether
HuNoVs preferentially target specific regions of the intestine like
MuNoVs. NoVs spread systemically at a low level to peripheral
tissues potentially via the hematogenous route. Supporting
viremia as the mode of spread is the reported detection of
HuNoV genomes in the serum of infected people (Takanashi
et al., 2009). However, it should be recognized that many groups
have failed to detect HuNoV viremia, so this may not be a com-
mon feature of infection. A requirement for dendritic cells for ex-
traintestinal spread of a MuNoV has also been reported (Elftman
et al., 2013). Finally, NoVs are shed fecally for variable lengths of
time (discussed in more detail below). As illuminated by MuNoV
studies, there are virus strain-dependent variations in the magni-
tude and duration of shedding. For example, shedding is quite
low for certain MuNoV strains but can reach R108 genomes
per gram feces for other strains (Arias et al., 2012; Thackray
et al., 2007), comparable to levels observed in HuNoV infections.
Elucidating NoV virulence determinants is another active
research area (Figure 1). These studies have been facilitated by
the identification of MuNoV strains with distinct pathogenic
properties, MuNoV cell culture adaptation studies, and MuNoV
RNA secondary structure analysis. One known MuNoV virulence
determinant is the P domain of VP1 (Bailey et al., 2008; StrongCell Host & Microbe 15, June 11, 2014 ª2014 Elsevier Inc. 671
Table 1. Features of NoV Animal Models
Host Virus Strain Route In Vivo Viral Antigen Intestinal Disease
Fecal
Shedding
(dpi) Viremia
Stomach
Tropisma
Small
Intestinal
Tropisma
Large
Intestinal
Tropisma
MLN
Tropisma
Peripheral
Tissue
Tropisma References
Humans HuNoVs peroral intestinal monocytesb,
lamina propria cells
severe diarrhea
and vomiting
+ (widely
variable)
+/ N/A + N/A N/A N/A Chan et al., 2011;
Green, 2013; Lay
et al., 2010
Chimpanzees HuNoV GI.1 peroral;
intravenous
intestinal DC and
B cells
asymptomatic + (2–42) – N/A + N/A N/A + Bok et al., 2011;
Wyatt et al., 1978
Gnotobiotic pigs HuNoV GII.4 peroral IECs mild diarrhea + (1–4) + N/A + N/A N/A N/A Cheetham et al.,
2006
Gnotobiotic calves HuNoV GII.4 peroral IECs and intestinal
Mfb
mild diarrhea + (1–6) + N/A + N/A N/A N/A Souza et al., 2008
Balb/c RAG/gc/
mice
HuNoV GII.4
pool
intraperitoneal Mfb in spleen and
liver
asymptomatic – N/A + + + + + Taube et al., 2013
Wild-type mice MuNoVs peroral intestinal Mf and DCb asymptomatic + (1–R56) N/A +/ + + + +/ Arias et al., 2012;
Karst et al., 2003;
Mumphrey et al.,
2007; Thackray
et al., 2007
Interferon/ mice MuNoVs peroral Mf and DCb; IECs severe diarrhea + + + + + + + Karst et al., 2003;
Mumphrey et al.,
2007; Wobus et al.,
2004
Malnourished mice MuNoVs peroral N/A modest weight loss + (1–R50) N/A + + + + + Hickman et al.,
2014
aTropism is defined as detection of viral antigen in a tissue section by immunohistochemistry or titration of infectious virus or viral genomes from the indicated tissue.
bViral antigen detected in cells morphologically resembling monocytes, macrophages (Mf), and dendritic cells (DC).
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Table 2. Strengths and Weaknesses of NoV Animal Models
Model Strengths Weaknesses
HuNoV infection of chimpanzees -a similar course of infection compared to infection
of people
-genetic similarity between nonhuman primates and
people
-asymptomatic infection
-nonphysiological route of i.v. inoculation (although
chimpanzees are also susceptible to p.o. inoculation)
-not natural host
HuNoV infection of gnotobiotic
pigs and calves
-infectious orally
-causes mild diarrhea
-the poorly developed immune systems of gnotobiotic
hosts confounds immunity studies
-not natural host
HuNoV infection of Balb/c
RAG/gc/ mice
-ability to study HuNoVs in a tractable small animal
model
-asymptomatic infection
-nonphysiological route of i.p. inoculation
- immunodeficiency precludes immunity studies
-not natural host
MuNoV infection of wild-type
mice
-infectious orally
-ability to study NoV pathogenesis in a natural host
-genetic and environmental tractability of the murine
model
-in vitro cultivation permits genetic manipulation of
the virus
-asymptomatic infection
-not human pathogens
MuNoV infection of interferon/
mice
-infectious orally
-causes severe gastroenteritis
-immunodeficient nature of host
-systemic infection and disease not observed during
HuNoV infections
-not human pathogens
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virulence in STAT1/mice, whereas a glutamate at this position
is attenuating. However, the glutamate must afford a fitness
advantage to the virus, since it is routinely selected for in vitro
and in vivo (Bailey et al., 2008; Hickman et al., 2014; Wobus
et al., 2004). Another MuNoV virulence determinant is VF1 en-
coded by ORF4, which antagonizes the innate immune response
by blocking the induction of type I interferon (IFN) and regulating
virus-induced apoptosis in cultured cells (McFadden et al., 2011;
Thackray et al., 2007). MuNoV strains lacking VF1’s immunoreg-
ulatory activities are attenuated in vivo (McFadden et al., 2011;
Zhu et al., 2013). While certain human sapoviruses segregating
in a distinct Caliciviridae genus encode VF1, HuNoVs do not. Ev-
idence indicates that RNA structures in the NoV genome also
regulate viral virulence. A polypyrimidine (pY) tract within a
conserved stem-loop in the 30 untranslated region of the
MuNoV-1 genome, which binds cellular poly(rC) binding protein
and polypyrimidine tract binding protein, is not required for virus
replication in vitro, but its removal results in a partially attenuated
virus in STAT1/ mice (Bailey et al., 2010). Similarly, secondary
structure elements in NS3/4 and NS6/7 of MuNoV-3 enhance
viral fitness, although they are not required for replication
in vitro or persistence establishment in immunocompetent
mice (McFadden et al., 2013). It will be important in future inves-
tigations and as the necessary research tools become available
to validate these factors as virulence determinants of HuNoVs.
Overall, the available animal models to study NoV pathogen-
esis each have strengths and weaknesses, as summarized in
Table 2. Due to the significant limitations of studying HuNoVs
in their natural host and in cultured cells, the field is reliant
upon these animal models to uncover pathogenic mechanisms
and host-virus interactions. Although no model system can
perfectly mirror all aspects of infection in humans, there is a
strong likelihood that both HuNoV infection of non-natural hostsand nonhuman MuNoV infection of its natural host will continue
to inform many common features of HuNoV biology, including
general pathogenic mechanisms, replication strategies, and
immune responses.
Viral Persistence as a Possible Contributor to Spread
NoV infection in humans is generally considered an acute self-
limiting infection in themajority of the population, with symptoms
lasting between 24 and 72 hr. However, people continue to shed
virus after symptom resolution, and even asymptomatically in-
fected people can shed virus (Patterson et al., 1993; Rockx
et al., 2002). Moreover, a growing body of literature has high-
lighted the clinical importance of chronic long-termHuNoV infec-
tions in the immunocompromised (Bok and Green, 2012 and
references within). Patients on immunosuppressive therapy
due to solid organ or hematopoietic stem cell transplantation
may shed HuNoV for months to years (Alkhouri and Danziger-
Isakov, 2011; Saif et al., 2011). In many cases this is accompa-
nied by diarrhea, resulting in prolonged intestinal failure, often
requiring nutritional support, and further complicating patient
treatment (Saif et al., 2011). The relevance and impact of chronic
HuNoV shedders in outbreaks in both nosocomial environments
and community settings has yet to be fully evaluated, but prelim-
inary evidence suggests that they can be a source of nosocomial
outbreaks (Beersma et al., 2009). Nosocomial transmission be-
tween immunocompromised patients has also been observed,
despite the use of stringent infection control measures (Kundu
et al., 2013). Thus, prolonged shedding, in particular in the
context of chronic HuNoV infections of immunocompromised
patients, represents a putative factor in amplifying viral spread
in the population.
A related and critical area of study in the NoV field is eluci-
dating the role of chronic shedding in the emergence of new anti-
genic variants. It has been postulated by numerous groups thatCell Host & Microbe 15, June 11, 2014 ª2014 Elsevier Inc. 673
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emergence of phenotypically distinct viral variants (e.g., Sie-
benga et al., 2008). In the absence of strong immune pressure,
evidence suggests that the accumulation of mutations increases
the potential to generate antigenic variants (Bull and White,
2011). Interhost transmission studies suggest that minor variants
with a frequency of less than 0.01% of the population may trans-
mit between individuals (Bull and White, 2011), suggesting that
interhost transmission could be an important source selection
and may contribute to the emergence of variants with the poten-
tial to escape herd immunity. Thus, chronically infected people
may represent reservoirs of emergent HuNoV strains.
The MuNoV mouse model has provided insight into the viral
reservoirs and genetic determinants of persistence. Similar to
immunocompromised people chronically infectedwith a HuNoV,
severely immunocompromised RAG/ mice become chroni-
cally MuNoV infected (Karst et al., 2003). Furthermore, malnour-
ished mice that are delayed in clearing MuNoV infection display
reduced antiviral antibody responses and enhanced viral diver-
sity (Hickman et al., 2014), supporting the premise that immune
impairment creates an amenable environment for NoV evolution.
Even immunocompetent healthy mice become persistently in-
fected with certain MuNoV strains. Persistent MuNoV infection
in this context occurs primarily in the cecum and colon and is
associated with fecal shedding (Arias et al., 2012; Nice et al.,
2013). The nonstructural protein NS1/2—and specifically as-
partic acid to glutamic acid change at position 94 of NS1/2—
enhances colonic replication early after infection and allows
establishment of life-long persistent fecal shedding (Figure 1)
(Nice et al., 2013). This single amino acid change is accompanied
by a significant structural rearrangement of the N-terminal
domain of the protein (Borin et al., 2013). Unanswered questions
relating to MuNoV persistence include elucidating the mecha-
nism by which NS1/2 regulates colonic tropism and persistence
and determining whether the VF1 protein, previously shown to
antagonize the innate immune response inMuNoV-1 (McFadden
et al., 2011), contributes to viral persistence.
While there is some controversy in the field pertaining to the
temporal definition of persistence and whether NoV infection
meets these criteria, the shedding of NoVs long after the symp-
tomatic stage of infection—and even from asymptomatically
infected hosts—is clearly of potential importance in disease
epidemiology. The mechanisms used by most viruses for acute
replication differ from those utilized to evade the immune system
and replicate continuously for persistence. Identifying and tar-
geting viral mechanisms facilitating low-level prolonged infection
could have a significant impact on prevention strategies by elim-
inating persistent shedding and, thus, disease incidence in the
population as a whole.
Immune Mechanisms of Norovirus Control
The elucidation of immune mechanisms controlling primary NoV
infections and mediating protective immunity to rechallenges
has been greatly advanced by the use of NoV animal models,
as reviewed in this section.
Immune Control of Primary Norovirus Infections
Consistent with the short duration of NoV symptoms, innate
immunity—and, in particular, type I IFNs—is critical for control-
ling acute NoV infections. The MuNoV-1 system has also been674 Cell Host & Microbe 15, June 11, 2014 ª2014 Elsevier Inc.used to explore the molecular basis of IFN sensitivity (Changotra
et al., 2009; Karst et al., 2003) and the role of MDA5 in NoV RNA
sensing (McCartney et al., 2008). At least one mechanism of IFN
action was linked to an inhibition of viral genome translation
(Changotra et al., 2009). The effect of IFN-g onMuNoV-1 replica-
tion has also indicated a role of the Atg5-Atg12/Atg16L1
autophagy protein complex in mediating the antiviral effect, in-
dependent of canonical degradative autophagy (Hwang et al.,
2012). Further highlighting the protective role of type I IFN, inoc-
ulating gnotobiotic pigs with human IFN-a p.o. during GII.4
HuNoV infection significantly reduces fecal shedding (Jung
et al., 2012). Furthermore, mice lacking type I and II IFN recep-
tors, type I IFN receptor only, or STAT-1 have titers significantly
higher than those of wild-type mice and succumb to lethal
MuNoV infections (Karst et al., 2003; Thackray et al., 2012).
This disease is associated with rapid weight loss, severe diar-
rhea, gastric bloating, and pathology in intestinal and peripheral
tissues (Kahan et al., 2011; Karst et al., 2003; Mumphrey et al.,
2007; Rocha-Pereira et al., 2013). The antiviral effect of type I
IFN by macrophages and dendritic cells, as well as IFN regu-
latory factor 3 (IRF-3) and IRF-7, contribute to MuNoV control
but are dispensable in preventing lethal infections (Thackray
et al., 2012). In the absence of type I IFN, a role for type II IFN
in controlling MuNoV infections via a mechanism that requires
IRF-1 and the autophagy protein Atg5 has also been revealed
(Hwang et al., 2012; Karst et al., 2003; Maloney et al., 2012).
Components of the adaptive immune response also contribute
to the control and clearance of primary NoV infections. People
and animals infected with NoV develop mucosal and peripheral
antiviral antibody responses that are important for viral clear-
ance. Mice lacking functional B cells fail to clear MuNoV-1
from MLNs, and transfer of immune serum or immune B cells
into persistently infected RAG1/ mice reduces viral loads
(Chachu et al., 2008a). Furthermore, MuNoV-3 immune serum
mediates partial protection from a primary infection in wild-
type and RAG1/ mice (Zhu et al., 2013). HuNoV and MuNoV
infections also stimulate CD4+ andCD8+ T cell responses (Linde-
smith et al., 2005, 2010). Mice infected with aMuNoV develop an
intestinal T cell response by 8 dpi (Tomov et al., 2013). Although
MuNoV-1-infected mice deficient in CD4+ or CD8+ T cells ulti-
mately clear the infection, transfer of immune CD4+ or CD8+
T cells into persistently infected RAG1/ mice reduces the
chronic viral burden (Chachu et al., 2008b; Tomov et al., 2013).
Moreover, transfer of immune CD4+ T cells into naive wild-type
or RAG1/ mice partially protects from primary infection (Zhu
et al., 2013). Overall, these studies suggest that B cells, CD8+
T cells, and CD4+ T cells all contribute to the control of primary
NoV infections.
Norovirus Protective Immunity Determinants
The design of effective vaccines is driven by understanding the
nature of the immune response that protects from a virulent
infection. However, elucidating the determinants of protective
immunity to a HuNoV challenge has been confounded by the
lack of a cell culture system and the repeated exposure of indi-
viduals to distinct virus strains over time. Early human volunteer
studies indicated that a subset of individuals fail to develop long-
term protective immunity upon experimental GI.1 HuNoV infec-
tion (Johnson et al., 1990; Parrino et al., 1977), while in others
resistance to GI.1 infection correlated with an early increase in
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contrast, GII.4 HuNoVs evolve in response to herd immunity (dis-
cussed below). Potential explanations for the apparently limited
efficacy of the immune system at protecting against secondary
HuNoV challenge include the possibility that NoVs elicit short-
term herd immunity of sufficient duration to drive the emergence
of antigenically distinct pandemic strains, but these immune re-
sponses wane over time, or that virus strain-specific and host
genetic differences in protective immunity induction are domi-
nant. There are supporting data for both explanations. In one hu-
man volunteer study, the duration of protective immunity to a
GI.1 HuNoV lasted up to 6months but waned after 2 years (John-
son et al., 1990). Protective immunity elicited by a single expo-
sure of aMuNoV also substantially waneswithin 6months (Karst,
2010b; Zhu et al., 2013). A recent mathematical model estimated
the duration of HuNoV immunity to be 4.1–8.7 years, again signif-
icantly shorter than the life-long immunity induced by some other
virus infections (Simmons et al., 2013).
With regard to virus strain-specific differences, even intraclus-
ter MuNoV strains sharing 87%genetic identity differ remarkably
in their ability to induce protective immunity (Liu et al., 2009; Zhu
et al., 2013). This differential protective immunity induction is in
part dictated by the ability of the MuNoV VP2 protein to regulate
APC maturation (Figure 1). Protective immunity to MuNoV re-
quires antiviral antibody and MHC class II-dependent CD4+
T cells, whereas type I IFN, type II IFN, and CD8+ T cells are
dispensable (Zhu et al., 2013). Consistent with findings for other
viruses, multiple exposures to a homologous NoV boosts the
magnitude and duration of protective immunity. For example, a
single exposure to live MuNoV-1 elicits weak, waning immunity
(Karst, 2010b; Liu et al., 2009; Zhu et al., 2013), while a prime:
boost elicits robust, long-lived immunity (Chachu et al., 2008b).
While a single exposure to a GI.1 HuNoV elicits protective homo-
typic immunity in chimpanzees that lasts up to 10 months, a
prime:boost regimen elicits protection lasting at least 24 months
(Bok et al., 2011). Importantly, systemic vaccination with a non-
replicating viral vector elicits protection against enteric infection
in the murine system, raising important questions about the rela-
tive importance of mucosal versus systemic immunity for NoVs.
Protective immunity in these models requires antiviral antibody
and a CD4+ T cell response (Chachu et al., 2008a, 2008b). It
will be important in the future to confirm whether MuNoV obser-
vations regarding immune and viral determinants of protective
immunity translate to HuNoVs.
Noroviruses Are under Humoral Selection
Seroprevalence studies suggest that humans are exposed to
HuNoVs frequently, with seropositivity rates reaching >90%
worldwide in adulthood (e.g., Son et al., 2013). Analysis of mono-
clonal antibodies raised against HuNoV VLPs has demonstrated
the development of a wide spectrum of antibodies with strain-,
genotype-, genogroup-, or intergenogroup-specific reactivities.
While strain-specific epitopes are located in the hypervariable
P2 domain of VP1 (e.g., Allen et al., 2009; Debbink et al.,
2012), more broadly cross-reactive epitopes are located in
conserved regions of the S and P1 domains (e.g., Higo-Morigu-
chi et al., 2014). Although classical HuNoV neutralization assays
cannot be performed due to the lack of a cell culture system, a
widely used surrogate assay (blockade assay) measures theability of antibodies to block VLP binding to histo-blood group
antigens (HBGAs), which are viral attachment factors on the in-
testinal epithelium (Harrington et al., 2002). The presence of
such blockade antibodies correlates with resistance to infection
(e.g., Atmar et al., 2011), providing support that this is a biolog-
ically relevant indicator of protective immunity. Such blockade
studies have highlighted the correlation between the genetic
evolution of HuNoV genotypes and the ability to escape
blockade antibody responses. For example, the GII.4 cluster,
which is most often associated with HuNoV outbreaks, un-
dergoes genetic drift to cause epidemics every 2–3 years (Bull
and White, 2011; Estes et al., 2006). By analyzing the ability of
antibodies to block HBGA binding by epidemic GII.4 strains, it
was determined that genetic differences between virus strains
result in differential antibody recognition (Debbink et al., 2013;
Lindesmith et al., 2011, 2012). Thus, herd immunity is one impor-
tant factor that drives evolution of GII.4 strains (a topic of
frequent reviews, e.g., Bull and White, 2011; Donaldson et al.,
2010).
While there is extensive evidence for GII.4 evolution in
response to population immunity resulting in the emergence of
antigenically distinct virus strains, accumulating data suggest
genogroup- and even genotype-specific distinctions in HuNoV
evolutionary potential. For example, genogroup I viruses are
genetically stable compared to GII.4 viruses. Consistent with
this, human sera from GI.1-challenged volunteers contained
blockade responses effective against multiple genogroup I ge-
notypes (Lindesmith et al., 2010). The GII.2 cluster also acquires
limited antigenic changes in its VP1 protein (Swanstrom et al.,
2014). Interestingly, GII.3 viruses, which are predominantly asso-
ciated with pediatric infections, evolve as rapidly as GII.4 viruses
at the genomic level but revert back to previously used residues
at the protein level (Boon et al., 2011). Thus, serum antibody re-
sponses directed against GII.3 viruses are highly cross-reactive
at the intragenotype level (Mahar et al., 2014). The inability to
evolve away from herd immunity may be one explanation for
the limited prevalence of the GII.3 genotype in the adult popula-
tion, but future studies investigating blockade antibody re-
sponses are needed to support this hypothesis.
While the HuNoV antibody response is clearly complex, a
pattern emerges whereby highly cross-reactive antibody re-
sponses are directed to conserved epitopes in the VP1 S and
P1 domains, while strain/variant-specific antibodies are directed
to hypervariable regions of the P2 domain.When these hypervar-
iable regions in the P2 domain overlap with HBGA binding sites,
changes in antibody binding patterns correlate with changes in
antibody blockade responses, which represent at least part of
the neutralizing immune response. The relative ratio of each
type of antibody response (cross-reactive versus specific) and
the antibody blockade response to heterologous viruses within
and between genotypes appear to vary between genogroups I
and II, but future studies are needed to investigate additional
genotypes. Such increased understanding of the antigenic rela-
tionships and evolution of the many HuNoV strains will greatly
facilitate the development of effective HuNoV vaccines.
Development of Antiviral Drugs for Norovirus Infections
While no antiviral drugs for the prevention or treatment of NoV in-
fections are approved for human use, technical advances in theCell Host & Microbe 15, June 11, 2014 ª2014 Elsevier Inc. 675
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replicon cells (Chang et al., 2006) and the MuNoV cell culture
system (Wobus et al., 2004), have led to an explosion of research
activities in this area. For detailed descriptions of antiviral
approaches for controlling NoVs, the reader is referred to other
recent reviews (Arias et al., 2013; Kaufman et al., 2014).
An increasing number of NoV protein structures are being
solved, enabling the design of antiviral drugs through in silico
modeling. Since many structural features are conserved across
the NoV family, this approach has the potential to yield inhibitors
effective against the wide diversity of NoV strains. To date, a
multitude of candidate inhibitors, primarily targeting the viral
Pro, RdRp, and VP1, have been tested in recombinant protein
or cell-based assays, with activities typically in the low micro-
molar range (Arias et al., 2013; Kaufman et al., 2014). The only
drug candidate tested in vivo so far is the nucleoside analog
20-C-methylcytidine (2CMC) (Rocha-Pereira et al., 2013). Mice
lacking type I and II IFN receptors infected with MuNoV-1 and
treated twice daily subcutaneously with 50 mg/kg of 2CMC for
7 days show decreased viral replication in the intestine, shed
fewer viruses, are protected from virus-induced diarrhea and
mortality, develop protective immunity, and are protected from
rechallenge. While 2CMC was withdrawn as a hepatitis C virus
inhibitor because of side effects, these studies suggest that
nucleoside analogs in use or in development against other
viruses could be considered for development as treatment
options for NoV infections and/or in limiting viral spread.
Attempts tomodulate the host or target host-encoded viral-in-
teracting proteins to limit NoV infections are in the early stages.
To date, inhibition of cellular deubiquitinases and addition of type
I IFN have been tested in vivo for their ability to inhibit NoV infec-
tions. WP1130 is a promising small molecule inhibitor of a subset
of deubiquitinases that reduces MuNoV-1 titers in the small in-
testine (Perry et al., 2012). The therapeutic activity of IFN-a
against a HuNoV was demonstrated in gnotobiotic pigs (Jung
et al., 2012); however, the known side effects of IFN-a adminis-
tration likely limit its general use as a NoV treatment option. Sub-
stances from natural products with known safety profiles and
antimicrobial activities are another therapeutic avenue being
pursued, although the mechanism(s) of action is generally poorly
understood for these substances (Li et al., 2013).
In summary, an array of approaches and compounds are
under investigation to develop effective and safe NoV therapeu-
tics, including ones with pan-anti-NoV activities. Based on con-
cerns about the emergence of viral variants displaying resistance
to antiviral drugs when targeting a single viral protein, future
studies will likely expand into combination therapy targetingmul-
tiple antiviral pathways simultaneously.
Norovirus Vaccine Development
Extensive studies have documented the immunogenicity of NoV
VLPs comprised of the VP1 protein in animal models and hu-
mans (e.g., Atmar and Estes, 2012; Richardson et al., 2013).
Accordingly, ongoing HuNoV vaccine work focuses on immu-
nizing with VLPs. Chimpanzees receiving GI.1 VLPs in a
prime:boost intramuscular immunization regimen elicit homolo-
gous protection lasting at least 18 months (Bok et al., 2011).
Gnotobiotic pigs administered GII.4 VLPs plus adjuvant in one
oral followed by two intranasal inoculations are protected from676 Cell Host & Microbe 15, June 11, 2014 ª2014 Elsevier Inc.live virus infection 28 days later (Souza et al., 2007). Mice
receiving Venezuelan equine encephalitis viral replicons ex-
pressing the MuNoV-1 VP1 protein in a prime:boost footpad
immunization regimen are protected for up to 6 months (Chachu
et al., 2008b).
In addition to data from animal models, recent clinical trials in
humans have shown promise. A randomized phase I/II clinical
trial testing the efficacy of GI.1 HuNoV VLPs plus adjuvant
demonstrated modest protection. Volunteers administered
either VLP + adjuvants (n = 38) or placebo (n = 39) in two intra-
nasal doses were challenged with live virus 3 weeks later.
Vaccinated subjects exhibited reduced gastroenteritis (37% of
vaccinees versus 69% of placebo recipients) and incidence of
infection (61% of vaccinees versus 82% of placebo recipients)
(Atmar et al., 2011). In general, the presence of prechallenge
antibodies capable of blocking VLP binding to its respective
HBGA correlated with protection against infection and illness.
A more recent phase I/II trial tested intramuscular prime:boost
inoculation of a bivalent vaccine comprised of a GI.1 and a
GII.4 VLP plus adjuvant followed by challenge with a GII.4
HuNoV. Incidence and severity of disease were significantly
reduced in the vaccinated (n = 56) versus the placebo group
(n = 53) (Bernstein, 2013).
Recent work in the MuNoV model system demonstrated that
malnourished mice develop a severely reduced mucosal IgA
response to MuNoV-1 (although their antiviral serum IgG
response is fairly normal); decreased mucosal antiviral antibody
correlates with a lack of protective immunity to a secondary chal-
lenge as assessed by reductions in viral titers and intestinal fluid
accumulation as a measure of disease (Hickman et al., 2014).
These findings raise concerns that malnourished people will
mount ineffective or significantly reduced immunity to a HuNoV
vaccine, an outcome that would be consistent with other vac-
cines (von Bubnoff, 2011; Haque et al., 2014; Qadri et al.,
2013). It will be important to consider the impact of inoculation
route in future studies of vaccine efficacy in malnourished hosts.
Another major barrier to HuNoV vaccine development is the
extreme genetic heterogeneity within the virus family. Several
lines of investigation have revealed a lack of intergenogroup
cross-protection. For example, an early human challenge study
demonstrated that prior GI.1 infection fails to elicit protection
from a subsequent GII.1 infection (Wyatt et al., 1974). Similarly,
chimpanzees immunized with genogroup II VLPs fail to generate
protective immunity to a GI.1 challenge, although they elicit a
robust homotypic serum antibody response (Bok et al., 2011).
It is thus likely that an effective vaccine formulation will need to
minimally include genogroup I and II VLPs. Based on the
frequent emergence of dominant GII.4 HuNoV strains that
appear to display antigenic variability, it is also probable that
the GII VLP will require periodic modifications, similar to the
strategy used for updating seasonal influenza virus vaccines.
Collectively, VLP-based NoV vaccines show great promise, but
concerns remain about the duration, breadth, and magnitude
of the immune responses elicited by these nonreplicating anti-
gens. Similar concerns have plagued the HIV and influenza virus
fields for many years. New technologies for isolating human
monoclonal antibodies that are broadly neutralizing against
highly genetically diverse virus families have revolutionized these
fields (reviewed by Burton et al., 2012). The first human
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some of them being broadly reactive with a panel of GII.4 HuNoV
strains (Lindesmith et al., 2012). Furthermore, work in theMuNoV
model shows that administration of monoclonal antibodies
effectively reduces viral titers (Kolawole et al., 2014). Thus,
broadly reactive HuNoV antibodies may offer promise as treat-
ment options for new NoV vaccine strategies.Outlook
The last decade has seen remarkable advances in the molecular
virology and immunology of NoVs as summarized in this review.
The field is now ripe tomove forward, armedwith knowledge that
a major human disease may be overcome by sustained
advances in the laboratory. The efficacy of the first human vac-
cine trial provides a major boost for this field, enabling one to
envision a major reduction in the disease burden associated
with these important human pathogens.
The tools for this progress are now largely in place due to rapid
progress over the last 10–12 years. Primary among these is the
finding that MuNoV is an enteric virus sharing many pathogenic
properties with its human relatives that can be studied in the
genetically tractable mouse system. Further, MuNoV replicates
robustly in cultured cells, allowing the development of molecular
clones of NoV strains with different properties and easy muta-
genesis, which has shepherded the advancement of molecular
NoV pathogenesis and immunity.
A major limitation of the MuNoV system that remains is the lack
of acute gastroenteritis in wild-type mice infected with currently
available strains. This has created controversy in the field re-
garding whether the mouse model has value for analysis of NoV
biology and pathogenesis. Ultimately, all animal models have
certain drawbacks, but their utility to illuminate in vivo virus-host
interactions provides otherwise unattainable insights into viral
pathogenesis and the opportunity to derive in-depth understand-
ing of fundamental processes in immunity and pathogenesis.
Other animals models, including nonhuman primates, pigs, and
immunocompromised mice infected with HuNoVs, can no doubt
serve as parallel systems. Collectively, these animal models are
illuminating determinants of NoV protective immunity and our un-
derstanding of the possible role of persistent NoV infection in viral
spread. On the molecular virology side, newly developed tools
include a replication system for an animal virus closely related to
the human pathogens and replicon systems for HuNoVs.
Areas of NoV research that await investigation include (i)
developing HuNoV propagation systems; (ii) elucidating mecha-
nisms used by NoVs to elicit enteric pathology; (iii) designing
anti-NoV drugs that are safe and effective, especially in critical
target populations such as the immunocompromised; (iv) opti-
mizing vaccine strategies to enhance their efficacy across the
genetically diverse HuNoV strains; and (v) interrogating the
impact of NoV infection on the long-term health of the gut, as
the complex relationships between intestinal microbial commu-
nities, mucosal immunity, environmental factors, and host ge-
netics are becoming better understood.ACKNOWLEDGMENTS
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